Literature DB >> 17564755

Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.

T Müller1, L Ander, K Kolf, D Woitalla, S Muhlack.   

Abstract

The interval of line tracing performance is more associated to basal ganglia function due to the dependence on bradykinesia and rigidity. The other component of this task, the precision of execution of complex movement sequences, is more related to attention. We compared the motor response after once dosing of 200 mg retarded release LD (levodopa)/CD (carbidopa) and of 150 mg LD/CD/EN (entacapone) by rating of motor symptoms, by measurement of LD- and 3-O-methyldopa (3-OMD) plasma concentrations and by the outcomes of a line tracing task. Thirteen treated patients with Parkinson's disease (PD) took one of the two tested LD formulations on two consecutive days under randomised, double blind, identical standardised conditions. No significant differences appeared regarding rated motor response and LD plasma concentrations, but 3-OMD only significantly went up after LD/CD intake. LD/CD/EN was superior to LD/CD regarding the attention related components of line tracing probably due to a hypothetically increased dopamine occurrence at the prefrontal cortex, which guides human behaviour.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17564755     DOI: 10.1007/s00702-007-0773-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  18 in total

1.  Patterns of regional brain activation associated with different forms of motor learning.

Authors:  M Ghilardi; C Ghez; V Dhawan; J Moeller; M Mentis; T Nakamura; A Antonini; D Eidelberg
Journal:  Brain Res       Date:  2000-07-14       Impact factor: 3.252

Review 2.  Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions.

Authors:  Amy F T Arnsten; Bao-Ming Li
Journal:  Biol Psychiatry       Date:  2005-06-01       Impact factor: 13.382

3.  Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

Authors:  G Block; C Liss; S Reines; J Irr; D Nibbelink
Journal:  Eur Neurol       Date:  1997       Impact factor: 1.710

4.  3-O-methyldopa and motor fluctuations in Parkinson's disease.

Authors:  G Fabbrini; J L Juncos; M M Mouradian; C Serrati; T N Chase
Journal:  Neurology       Date:  1987-05       Impact factor: 9.910

5.  Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group.

Authors:  W C Koller; J T Hutton; E Tolosa; R Capilldeo
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

Review 6.  Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.

Authors:  J G Nutt
Journal:  Neurology       Date:  2000       Impact factor: 9.910

7.  Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients.

Authors:  Thomas Muller; Sabiene Benz; Horst Przuntek
Journal:  Can J Neurol Sci       Date:  2002-02       Impact factor: 2.104

8.  Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism.

Authors:  Michael J Frank
Journal:  J Cogn Neurosci       Date:  2005-01       Impact factor: 3.225

9.  Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease.

Authors:  Thomas Müller; Wilfried Kuhn; Thorsten Schulte; Horst Przuntek
Journal:  Neurosci Lett       Date:  2003-03-13       Impact factor: 3.046

Review 10.  Dopamine: a key regulator to adapt action, emotion, motivation and cognition.

Authors:  André Nieoullon; Antoine Coquerel
Journal:  Curr Opin Neurol       Date:  2003-12       Impact factor: 5.710

View more
  3 in total

1.  Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients.

Authors:  Thomas Müller; Siegfried Muhlack
Journal:  J Neural Transm (Vienna)       Date:  2014-01-05       Impact factor: 3.575

2.  Peripheral COMT inhibition prevents levodopa associated homocysteine increase.

Authors:  Thomas Müller; Siegfried Muhlack
Journal:  J Neural Transm (Vienna)       Date:  2009-08-06       Impact factor: 3.575

3.  Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference.

Authors:  Thomas Müller
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.